Malignant melanoma: Prevention, early detection, and treatment in the 21st century

Ca-A Cancer Journal for Clinicians

Volumn 50, Issue 4, 2000, Pages 215-236

  Rigel, Darrell S ^a   Carucci, John A ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIGEN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CANCER VACCINE; CARMUSTINE; CISPLATIN; DACARBAZINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LOMUSTINE; SUNSCREEN; TAMOXIFEN; TEMOZOLOMIDE; THYMIDINE KINASE; VINCRISTINE;

ARTICLE; AWARENESS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; GENE THERAPY; HEALTH EDUCATION; HEALTH PRACTITIONER; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLIC HEALTH; SELF EXAMINATION; SKIN EXAMINATION; SUN EXPOSURE; SURVIVAL RATE; ULTRAVIOLET RADIATION;

EID: 0033837128     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.50.4.215     Document Type: Article

References (123)

1. Cancer statistics, 2000
2. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking
3. Diagnosis and treatment of early melanoma
4. Predicting ten-year survival of patients with primary cutaneous melanoma: Corroboration of a prognostic model
5. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century
6. Melanoma incidence: If it quacks like a duck
7. The dangers of atypical mole (dysplastic nevus) syndrome. Teaching at-risk patients to protect themselves from melanoma
8. Risk of cutaneous malignant melanoma in patients with nonfamilial atypical nevi from a pigmented lesions clinic
9. The etiology of malignant melanoma
10. Histopathologic diagnosis of dysplastic nevi: Concordance among pathologists convened by the World Health Organization Melanoma Programme
11. The Danish case-control study of cutaneous malignant melanoma. IV. No association with nutritional factors, alcohol, smoking or hair dyes
12. Identification of those at highest risk for development of malignant melanoma
13. The epidemiology of skin cancer
14. The genetics of hereditary melanoma and nevi: 1998 update
15. Atypical mole syndrome: Risk factor for cutaneous malignant melanoma and implications for management
16. Parallel risk assessment of melanoma and basal cell carcinoma: Skin characteristics and sun exposure
17. Molecular staging of malignant melanoma: Correlation with clinical outcome
18. Cutaneous neoplasms in a military population of HIV-1-positive patients. Military Medical Consortium for the Advancement of Retroviral Research
19. PUVA and cancer risk: The Swedish follow-up study
20. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study
21. Do tanning lamps cause melanoma? An epidemiologic assessment
22. Melanoma risk by age and socioeconomic status
23. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations
24. Genetic and environmental influences in the development of multiple primary melanoma
25. Malignant melanoma
26. Cancer family syndrome associated with multiple malignant melanomas and a malignant fibrous histiocytoma
27. Risk factors for the development of malignant melanoma- I: Review of case-control studies
28. High risk of malignant melanoma in melanomaprone families with dysplastic nevi
29. Plantar melanoma: Is the incidence of melanoma of the sole of the foot really higher in blacks than whites?
30. Epidemiology and prognostic factors in malignant melanoma
31. Risk factors for the development of melanoma, in National Clinical Dermatology Conference, Chicago
32. Cutaneous malignant melanoma and sun exposure in Spain
33. Multiple primary melanoma
34. Multiple primary cutaneous melanomas
35. Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: A case-control study
36. A locus linked to p16 modifies melanoma risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families
37. An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma
38. Five novel somatic CDKN2/p16 mutations identified in melanoma, glioma and carcinoma of the pancreas. Mutations in brief no. 170. Online
39. Familial melanoma; CDKN2A and beyond
40. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds
41. Consumer education makes difference
42. Sun exposure, pigmentary traits, and risk of cutaneous malignant melanoma: A case-control study in a Mediterranean population
43. Relationship between risk factors, knowledge and preventive behaviour relevant to skin cancer in general practice patients in south Australia
44. Melanoma in Kauai, Hawaii, 1981-1990: The significance of in situ melanoma and the incidence trend
45. What is the evidence for a sunscreen and melanoma controversy?
46. Malignant melanoma in the 1990s: The continued importance of early detection and the role of physician examination and self-examination of the skin
47. Pedunculated Malignant Melanoma
48. Malignant melanoma-clinical diagnostic techniques
49. Clinicopathological correlation of pigmented skin lesions using dermoscopy
50. The role of the pathologist in the diagnosis of melanoma
51. Mohs micrographic surgery using HMB-45 for a recurrent acral melanoma
52. The reliability of frozen sections in the evaluation of surgical margins for melanoma
53. Mohs micrographic surgery for melanoma
54. Mohs micrographic surgery for the treatment of in situ nail apparatus melanoma: A case report
55. Cutaneous malignant melanoma treated by Mohs surgery. Review of the treatment results of 179 cases from the Mohs Melanoma Registry
56. Diagnosis of pigmented skin lesions by epiluminescence microscopy: Determinants of accuracy improvement in a nationwide training programme for practical dermatologists
57. Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma
58. Epiluminescence microscopy in clinical diagnosis of pigmented skin lesions?
59. Epiluminescence microscopy-based classification of pigmented skin lesions using computerized image analysis and an artificial neural network
60. Computer-assisted analysis of epiluminescence microscopy images of pigmented skin lesions
61. Automated epiluminescence microscopy: Human vs machine in the diagnosis of melanoma
62. The diagnosis of breast cancer
63. What promotes skin self-examination?
64. Screening for melanoma and skin cancer
65. Evaluation of the American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program
66. Is the ounce of screening and prevention for skin cancer worth the pound of cure?
67. Who is being screened for melanoma/skin cancer? Characteristics of persons screened in Massachusetts
68. Follow-up recommendations for patients with stage I malignant melanoma
69. Recent advances in melanoma staging and therapy
70. New approaches to the systemic treatment of melanoma
71. The treatment of metastatic melanoma with chemotherapy and biologics
72. What's new in the treatment of cutaneous melanoma?
73. Surgical margins for excision of primary cutaneous melanoma
74. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. A follow-up study
75. Mohs micrographic surgery for the treatment of primary cutaneous melanoma
76. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
77. The tumor biology of melanoma nodal metastases
78. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients
79. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991
80. Elective lymph node dissection (ELND) for malignant melanoma
81. Surgical management of regional lymph nodes in primary cutaneous malignant melanoma
82. Surgical management of patients with intermediate thickness melanoma: Current role of elective lymph node dissection
83. Sentinel node biopsy in patients with cutaneous melanoma
84. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase- polymerase chain reaction in early-stage melanoma patients
85. Sentinel lymphadenectomy for patients with clinical stage I melanoma
86. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin
87. Current treatment options for malignant melanoma
88. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921)
89. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma
90. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a
91. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma
92. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
93. Systemic adjuvant treatment of high-risk melanoma: The role of interferon alfa-2b and other immunotherapies
94. Perspective on allogeneic melanoma lysates in active specific immunotherapy
95. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group study
96. Eastern cooperative group trial of interferon gamma in metastatic melanoma: An innovative study design
97. Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma
98. Interleukin 2 and lymphokine-activated killer cell therapy: Analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen
99. Phase I evaluation of combination therapy with interleukin 2 and gamma- interferon
100. The role of interleukin-2 in the management of stage IV melanoma: The EORTC melanoma cooperative group program
101. Dacarbazine and interferon alpha for stage IV malignant melanoma
102. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
103. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local- regional metastases
104. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center experience
105. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy
106. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha
107. Human tumor antigens: Implications for cancer vaccine development
108. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti- high-molecular-weight-melanoma-associated antigen monoclonal [published erratum appears in J Clin Invest 1991 Feb;87(2):757]
109. Update on active specific immunotherapy with melanoma vaccines
110. Melan-A/MART-1 (51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells
111. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
112. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
113. The new melanoma markers: MART-1 and Melan-A (the NIH experience)
114. New perspectives on immunobiology and immunotherapy of melanoma
115. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
116. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma
117. Dendritic cell vaccines for cancer immunotherapy
118. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
119. Immune and gene therapy for melanoma, and the immunobiology of melanoma
120. Cancer gene and immunotherapy: Recent developments
121. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma
122. Intratumoral recombinant GM-CSF- encoding virus as gene therapy in patients with cutaneous melanoma